Global X Genomics & Biotechnology ETF
GNOM - ETF AI Analysis
Top Page
Global X Genomics & Biotechnology ETF (GNOM)
GNOM, the Global X Genomics & Biotechnology ETF, has a solid overall rating that reflects a mix of strong growth stories and meaningful financial risks in the genomics and biotech space. Higher-quality holdings like Vertex Pharmaceuticals, Qiagen, Illumina, and Natera support the fund’s rating through robust financial performance, positive earnings sentiment, and strong technical momentum, while weaker names such as Twist Bioscience and some loss-making, volatile holdings limit the score due to profitability and valuation concerns. The main risk factor is the fund’s concentration in a single, specialized sector where many companies face ongoing losses, cash flow challenges, and valuation pressures, making it more sensitive to industry downturns.
GNOM vs. SPDR S&P 500 ETF (SPY)
- AUM
- 116.99M
- Region
- Global
- Expense Ratio
- 0.50%
- Beta
- 1.14
- Issuer
- Global X
- Inception Date
- Apr 05, 2019
- Dividend Yield
- 1.05%
- Asset Class
- Equity
- Index Tracked
- Solactive Genomics Index
GNOM Summary
GNOM is the Global X Genomics & Biotechnology ETF, which follows the Solactive Genomics Index and focuses on companies using DNA and gene science to improve healthcare. It holds firms working on gene editing, genetic testing, and personalized medicine. Well-known names in the fund include Moderna and Illumina, along with other specialized biotech companies. Someone might invest in GNOM to tap into the long-term growth potential of cutting-edge medical technologies while spreading their money across many genomics stocks. A key risk is that biotech shares can be very volatile, so the ETF’s price can swing sharply up or down.
How much will it cost me?
GNOM has an annual expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. This is higher than the average ETF because it’s a specialized, theme-focused fund in genomics and biotechnology rather than a broad, low-cost index fund.
What would affect this ETF?
GNOM could benefit if breakthroughs in gene editing, sequencing, and personalized medicine drive demand for its global healthcare and biotech holdings like Moderna, Illumina, and Vertex, and if governments and insurers support innovative treatments. On the downside, tighter drug regulations, clinical trial setbacks, changes in healthcare policy, or rising interest rates that make risky growth sectors less attractive could hurt genomics and biotechnology stocks in this ETF.
GNOM Top 10 Holdings
GNOM is a pure play on genomics, with nearly all its firepower aimed at health care innovators rather than broad market names. Moderna has been a key engine lately, rising on renewed optimism around its pipeline, while Illumina and Qiagen provide steadier support as core tools providers to the sequencing world. On the flip side, Twist Bioscience and 10x Genomics have seen more mixed, lagging action, occasionally acting like sandbags on performance despite their long-term promise. With holdings spanning the U.S. and Asia, GNOM offers a global but tightly focused bet on the future of biotech and gene-based medicine.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 12.71% | $14.87M | $90.38B | 794.91% | 59Neutral | |
| Twist Bioscience | 5.35% | $6.26M | $7.35B | 273.24% | 43Neutral | |
| 10x Genomics | 5.33% | $6.24M | $7.65B | 255.90% | 60Neutral | |
| Guardant Health | 5.28% | $6.18M | $20.52B | 61.16% | 61Neutral | |
| Illumina | 4.90% | $5.74M | $31.30B | 72.61% | 71Outperform | |
| Natera | 4.74% | $5.55M | $46.27B | 59.01% | 73Outperform | |
| Genscript Biotech | 3.68% | $4.30M | HKD 69.04B | 84.01% | 60Neutral | |
| Qiagen | 3.83% | $4.48M | $10.30B | 6.15% | 77Outperform | |
| Vertex Pharmaceuticals | 3.79% | $4.43M | $136.56B | 23.95% | 78Outperform | |
| Bio-Techne | 3.80% | $4.44M | $11.44B | 19.84% | 64Neutral |
GNOM Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Negative. The current price of 61.67 is below the 20-day moving average (MA) of 66.91, below the 50-day MA of 66.84, and above the 200-day MA of 54.55, indicating a neutral trend. The MACD of -0.91 indicates Positive momentum. The RSI at 40.19 is Neutral, neither overbought nor oversold. The STOCH value of 13.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNOM.
GNOM Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $61.67 | $67.00(8.64% Upside) | $116.99M | 0.50% | 61Neutral | |
| $76.20 | $82.49(8.25% Upside) | $961.94M | 0.40% | 62Neutral | |
| $49.96 | $81.98(64.10% Upside) | $827.94M | 0.70% | 56Neutral | |
| $35.44 | $52.74(48.80% Upside) | $831.44M | 0.75% | 70Outperform | |
| $53.72 | $72.54(35.04% Upside) | $705.39M | 0.65% | 61Neutral | |
| $40.10 | $52.44(30.76% Upside) | $344.31M | 0.47% | 57Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GNOM | Global X Genomics & Biotechnology ETF | 61.67 | 19.09 | 44.82% | |
| GII | SPDR S&P Global Infrastructure ETF | 76.20 | 7.76 | 11.34% | |
| BLOK | Amplify Transformational Data Sharing Etf | 49.96 | -7.74 | -13.42% | |
| IVES | Dan IVES Wedbush AI Revolution ETF | 35.44 | 3.75 | 11.83% | |
| ROBT | First Trust Nasdaq Artificial Intelligence & Robotics ETF | 53.72 | 3.09 | 6.11% | |
| IDNA | iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 40.10 | 14.25 | 55.14% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
